Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy. - Ishikawa S; Ouchi K; Wakayama S; Oyamada S; Iwasaki T; Numakura R; Yoshida Y; Taniguchi S; Kasahara Y; Komine K; Saijo K; Shirota H; et al. (European journal of cancer (Oxford, England : 1990), 2026)